Literature DB >> 23274969

The clinical and molecular significance of C4d staining patterns in renal allografts.

Nicole Hayde1, Yi Bao, James Pullman, Bin Ye, Brent R Calder, Monica Chung, Daniel Schwartz, Ahmed Alansari, Graciela de Boccardo, Min Ling, Enver Akalin.   

Abstract

BACKGROUND: We investigated the clinical and molecular significance of minimal peritubular capillary (PTC) and isolated glomerular C4d+ staining using microarrays.
METHODS: Two hundred fifty-five clinically indicated transplant biopsies were included in the analyses. C4d staining was performed on paraffin sections using a polyclonal rabbit anti-C4d antibody. Gene expression profiles in a subset of patients were studied using Affymetrix HuGene 1.0ST arrays.
RESULTS: Immunohistochemistry for C4d of 255 biopsies showed 51% C4d negative, 4% minimal PTC C4d+, 15% focal or diffuse PTC C4d+, and 31% isolated glomerular C4d+ biopsies. Patients with minimal and focal/diffuse PTC C4d+ staining had higher frequency of donor-specific anti-HLA antibodies (DSA) (67% and 82%) and antibody mediated rejection (AMR) (66% and 89%) when compared with C4d-negative biopsies (25% and 19%, respectively) (P<0.001). The glomerulitis, interstitial inflammation, and peritubular capillaritis scores were also significantly higher in minimal (0.88, 1.25, and 1.5) and focal/diffuse PTC C4d+ biopsies (0.65, 1.41, and 1.5), compared with C4d-negative biopsies (0.25, 079, and 0.34), respectively. There were no differences in the DSA frequency, AMR rate, or Banff scores between isolated glomerular C4d+ and C4d-negative patients. Although both minimal and focal/diffuse C4d+ biopsies showed increased expression of genes related to the immune response, interferon-gamma and rejection-induced, cytotoxic T cell and constitutive macrophage-associated pathogenesis-based transcripts, there was no activation of immune-response-related genes in isolated glomerular C4d+ biopsies.
CONCLUSION: Minimal PTC C4d+ staining but not isolated glomerular C4d+ staining is associated with AMR, circulating DSAs and immune-response-related gene activation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23274969     DOI: 10.1097/TP.0b013e318277b2e2

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  The clinical implications of the unique glomerular complement deposition pattern in transplant glomerulopathy.

Authors:  Priya S Verghese; Robin C Reed; Bu Lihong; Arthur J Matas; Youngki Kim
Journal:  J Nephrol       Date:  2016-11-15       Impact factor: 3.902

2.  Persistent C4d and antibody-mediated rejection in pediatric renal transplant patients.

Authors:  Andrew M South; Lynn Maestretti; Neeraja Kambham; Paul C Grimm; Abanti Chaudhuri
Journal:  Pediatr Transplant       Date:  2017-08-22

3.  The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy.

Authors:  Nicole Hayde; Yi Bao; James Pullman; Bin Ye; R Brent Calder; Monica Chung; Daniel Schwartz; Michelle Lubetzky; Maria Ajaimy; Graciela de Boccardo; Enver Akalin
Journal:  Clin J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 8.237

Review 4.  Transplant glomerulopathy.

Authors:  Edward J Filippone; Peter A McCue; John L Farber
Journal:  Mod Pathol       Date:  2017-10-13       Impact factor: 7.842

5.  Integrative Analyses of Circulating Small RNAs and Kidney Graft Transcriptome in Transplant Glomerulopathy.

Authors:  Canan Kuscu; Manjari Kiran; Akram Mohammed; Cem Kuscu; Sarthak Satpathy; Aaron Wolen; Elissa Bardhi; Amandeep Bajwa; James D Eason; Daniel Maluf; Valeria Mas; Enver Akalin
Journal:  Int J Mol Sci       Date:  2021-06-09       Impact factor: 5.923

6.  Diagnostic application of transcripts associated with antibody-mediated rejection in kidney transplant biopsies.

Authors:  Frederic Toulza; Kathy Dominy; Michelle Willicombe; Jack Beadle; Eva Santos; H Terence Cook; Richard M Szydlo; Adam McLean; Candice Roufosse
Journal:  Nephrol Dial Transplant       Date:  2022-07-26       Impact factor: 7.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.